The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer

Michael J Grant; Gavitt A Woodard; Sarah B Goldberg

doi:10.1016/j.hoc.2023.02.003

The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer

Hematol Oncol Clin North Am. 2023 Jun;37(3):513-531. doi: 10.1016/j.hoc.2023.02.003. Epub 2023 Apr 4.

Authors

Michael J Grant¹, Gavitt A Woodard², Sarah B Goldberg³

Affiliations

¹ Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA; Department of Medicine (Medical Oncology), Yale School of Medicine, 330 Cedar Street, Rm BB 205, New Haven, CT 06520, USA. Electronic address: Michael.grant@yale.edu.
² Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA; Department of Surgery, Yale School of Medicine, PO Box 208028, New Haven, CT 06520, USA.
³ Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA; Department of Medicine (Medical Oncology), Yale School of Medicine, 330 Cedar Street, Rm BB 205, New Haven, CT 06520, USA.

PMID: 37024389
DOI: 10.1016/j.hoc.2023.02.003

Abstract

During the last 2 decades, the understanding of non-small cell lung cancer (NSCLC) has evolved from a purely histologic classification system to a more complex model synthesizing clinical, histologic, and molecular data. Biomarker-driven targeted therapies have been approved by the United States Food and Drug Administration for patients with metastatic NSCLC harboring specific driver alterations in EGFR, HER2, KRAS, BRAF, MET, ALK, ROS1, RET, and NTRK. Novel immuno-oncology agents have contributed to improvements in NSCLC-related survival at the population-level. However, only in recent years has this nuanced understanding of NSCLC permeated into the systemic management of patients with resectable tumors.

Keywords: Circulating tumor DNA; Immune checkpoint inhibitors; Lung adjuvant cisplatin evaluation; Non-small cell lung cancer; Tumor microenvironment.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / pathology
Mutation
Protein-Tyrosine Kinases / genetics
Protein-Tyrosine Kinases / therapeutic use
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins / therapeutic use

Substances

Protein-Tyrosine Kinases
Proto-Oncogene Proteins